Code intelligence

FDA-BLA761119 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761119.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: VYEPTI (EPTINEZUMAB-JJMR) — Type 1 - New Molecular Entity

Policy FDA-BLA761119 · Neurology

High

VYEPTI (Eptinezumab-JJMR) is an injectable medication likely to receive a J-code for billing under Medicare Part B. Its category may allow for ASP+6% reimbursement, but billing teams should confirm th

View alert